Baby's hand holding its mother's finger

Newsroom

Latest News

News

Positive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting

February 4, 2016 – Sera Prognostics, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk (PAPR) study validate the newly available PreTRM® test, which accurately and objectively predicts spontaneous preterm birth (sPTB), in pregnant women whose blood is drawn for analysis as early as 19 weeks of pregnancy. The data were presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting in Atlanta, Georgia.
News

Sera Prognostics Announces Clinical Study Data Selected for Presentation at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting

January 7, 2016 — Sera Prognostics, Inc., a women’s healthcare company, today announced that findings from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study will be reported in an oral presentation during the Society for Maternal-Fetal Medicine’s (SMFM) 36th Annual Pregnancy Meeting™ in Atlanta, February 1-6, 2016.
News

Sera Prognostics to Present at 34th Annual J.P. Morgan Healthcare Conference

December 21, 2015–Sera Prognostics, Inc. today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming J.P. Morgan Healthcare Conference.
News

Sera Prognostics to Present at 27th Annual Piper Jaffray Healthcare Conference

November 24, 2015 – Sera Prognostics, Inc., today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the Piper Jaffray Healthcare Conference . Dr. Critchfield’s presentation will take place at 10:30 AM ET on Wednesday, December 2, 2015 at the Lotte New York Palace Hotel in New York, NY.
News

Sera Prognostics Announces Early Limited Commercial Access of its PreTRM™ Test

October 19, 2015 – Sera Prognostics, Inc., today announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth.
News

Sera Prognostics to Present at 33rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2014 – Sera Prognostics announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the 33rd annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015.
News

Sera Prognostics Closes $20 Million in Series B Financing

Jan 7, 2015 – Sera Prognostics announced that it has closed $20 Million in Series B financing, led by Chione, Ltd, a European investment company, and appointed Mansoor Raza Mirza, M.D. to its Board of Directors.
News

Arnold L. Oronsky, Ph.D., Joins Sera’s Board of Directors

Feb 24, 2015–Sera Prognostics announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Dr. Oronsky’s addition to the Sera board occurs as the company is in the final stages of developing PreTRM™, its novel proteomic predictor for preterm birth risk, prior to its commercial launch. In addition, Douglas Fisher, M.D., joins the company’s management team as Chief Business Officer.
News

Bill & Melinda Gates Foundation Has Agreed to Join Series B Financing

Feb 4, 2015-Sera Prognostics announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Series B financing, which will bring the total transaction to $25 million. The additional funding will help Sera expand the reach of its proteomic technology, to develop new tests designed to predict the risk of preterm birth for women in developing countries around the world.

Stay in Touch